Turnier JL, et al. - Using an unbiased proteomics approach, experts identified candidate urine biomarkers (CUBMs) that can predict LN chronicity and attempted to have them validated in a larger cohort. They used urine collected at kidney biopsy from 20 children with varying levels of LN damage. SERPINA3 (a known inhibitor of neutrophil cathepsin G and angiotensin II production) was identified as a potential urine biomarker to help quantify LN activity. LN chronicity degree was distinguished by none of the CUBMs in the validation cohort. Nonetheless, a moderate positive association of urine SERPINA3 with LN histological activity was noted.